Updates are available Correction dated 2021-09-14
Click to view Correction: https://doi.org/10.1038/s41590-021-01036-7
-
Authors
Burrows, Natalie http://orcid.org/0000-0001-6591-5971
Bashford-Rogers, Rachael J. M. http://orcid.org/0000-0002-6838-0711
Bhute, Vijesh J.
Peñalver, Ana
Ferdinand, John R.
Stewart, Benjamin J. http://orcid.org/0000-0003-4522-0085
Smith, Joscelin E. G. http://orcid.org/0000-0001-9271-1157
Deobagkar-Lele, Mukta http://orcid.org/0000-0002-8543-6801
Giudice, Girolamo
Connor, Thomas M.
Inaba, Akimichi
Bergamaschi, Laura
Smith, Sam
Tran, Maxine G. B.
Petsalaki, Evangelia http://orcid.org/0000-0002-8294-2995
Lyons, Paul A. http://orcid.org/0000-0001-7035-8997
Espeli, Marion
Huntly, Brian J. P. http://orcid.org/0000-0003-0312-161X
Smith, Kenneth G. C.
Cornall, Richard J.
Clatworthy, Menna R.
Maxwell, Patrick H. http://orcid.org/0000-0002-0338-2679
-
Funding
Funding for this research was provided by:
Wellcome Trust (19710, 097922/Z/11/Z, 100140, WT106068AIA, 19710, 19710, 19710, 19710, 19710, 097922/Z/11/Z, 100140)
Rosetrees Trust (G102721, G102721)
Cambridge NIHR senior investigator
RCUK | Medical Research Council (G0802266)
Lister Institute of Preventive Medicine (Summer studentship)
DH | National Institute for Health Research (CL-2006-14-006, RP-2017-08-ST2-002)
Chan-Zuckerberg Initiative Human Cell Atlas Technology Development GrantVersus Arthritis Cure Challenge Research Grant
Cambridge NIHR BRC
- License Information
-
More Information
Article History
Received: 20 December 2019
Accepted: 29 July 2020
First Online: 31 August 2020
Change Date: 14 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-021-01036-7
Competing interests
: P.H.M. is a scientific founder and equity holder of ReOx and has received speaker honoraria from Fibrogen, which both aim to develop PHD inhibitors as therapies. R.J.M.B-R. is a cofounder and consultant for Alchemab Therapeutics Ltd, which maps antibody repertoires to develop therapeutics for patients with hard-to-treat diseases, and is a consultant for Imperial College London and VHSquared, which develops Vorabodies (oral domain antibodies). R.J.C. is a scientific founder and equity holder of MIROBIO, which aims to develop new therapies to treat a range of autoimmune diseases. All other authors declare no competing interests.
